Sudden unexpected death in epilepsy

EpiWatch Closes Financing Round and Appoints New Directors

Retrieved on: 
Thursday, April 7, 2022

BALTIMORE, April 7, 2022 /PRNewswire/ -- EpiWatch, Inc., a digital health company focused on epilepsy, announced today the closing of its latest financing round and appointment of three new members to its Board of Directors.

Key Points: 
  • BALTIMORE, April 7, 2022 /PRNewswire/ -- EpiWatch, Inc., a digital health company focused on epilepsy, announced today the closing of its latest financing round and appointment of three new members to its Board of Directors.
  • "We are pleased to have closed our latest financing round, adding talented and experienced experts to our Board of Directors.
  • EpiWatch is initially developing a proprietary capability to detect and alert for potentially dangerous tonic-clonic (grand mal) seizures.
  • EpiWatch is a registered trademark of the Johns Hopkins University in the United States and other countries.

SK Life Science, Inc. Launches STEPS Toward Zero Movement to Educate, Inspire and Activate the Epilepsy Community

Retrieved on: 
Monday, August 2, 2021

We hope the STEPS Toward Zero movement inspires more discussion among members of the epilepsy community."

Key Points: 
  • We hope the STEPS Toward Zero movement inspires more discussion among members of the epilepsy community."
  • Additionally, as a part of the STEPS Toward Zero movement, SK life science is inviting the epilepsy community to join the conversation and share what zero seizures means to them by using #STEPSTowardZero on social media.
  • "SK life science's STEPS Toward Zero movement provides another platform to put the brains and stories of people with epilepsy at the center of conversations in order to facilitate education and connections and inspire others in the epilepsy community."
  • Epilepsy.

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

Retrieved on: 
Monday, August 2, 2021

Patients also suffer with life-threatening medically intractable seizures that may increase the risk of SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, or infections.

Key Points: 
  • Patients also suffer with life-threatening medically intractable seizures that may increase the risk of SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, or infections.
  • Dr. Hahn-Jun Lee, M.Sc., Ph.D., President and CEO of Epygenix Therapeutics, Inc. stated that the EMA's Orphan Medicinal Product Designation to EPX-200 is very important, as EMA recognizes the significant potential benefit of EPX-200 for DS treatment.
  • The Orphan Medicinal Product Designation from EMA for EPX-200 brings us one step closer to such positionto bring our drugs to patients in Europe more efficiently."
  • EPX-200 has already been successfully tested in five Dravet Syndrome patients at the University of Colorado Hospital, where it showed an ability to reduce seizure frequency in a small compassionate use trial.

Heart2Heart CPR Shines a Light on Sudden Unexpected Death in Epilepsy (SUDEP) by Sharing Kayla's Story

Retrieved on: 
Friday, March 26, 2021

In recognition of Epilepsy Awareness Day, Heart to Heart, is informing the public about a rare life threatening medical condition called Sudden Unexpected Death in Epilepsy (SUDEP ).

Key Points: 
  • In recognition of Epilepsy Awareness Day, Heart to Heart, is informing the public about a rare life threatening medical condition called Sudden Unexpected Death in Epilepsy (SUDEP ).
  • An awareness campaign on Sudden Unexpected Death in Epilepsy (SUDEP) , will take place immediately and this topic will be covered in all Heart to Hearts courses.
  • This includes Standard First Aid CPR , Emergency First Aid CPR , Basic Life Support, Instructor Development and Professional Responder programs.
  • We hope that by sharing Kaylas story we can both raise awareness and encourage research into Epilepsy and SUDEP.

Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

Retrieved on: 
Wednesday, November 25, 2020

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life.

Key Points: 
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life.
  • Patients enrolled to date are representative of patients with Dravet syndrome, and data collected indicate that the selected cognition measures are valid and appropriate for use in patients with Dravet syndrome.
  • The primary endpoints are safety, tolerability and pharmacokinetic profile of STK-001 in Dravet syndrome patients.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.

Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model

Retrieved on: 
Wednesday, August 26, 2020

Data published today in the journal Science Translational Medicine also showed that STK-001 achieved target engagement, pharmacologic activity and efficacy by selectively increasing Scn1a gene and Nav1.1 protein expression.

Key Points: 
  • Data published today in the journal Science Translational Medicine also showed that STK-001 achieved target engagement, pharmacologic activity and efficacy by selectively increasing Scn1a gene and Nav1.1 protein expression.
  • STK-001 is an antisense oligonucleotide (ASO) that was created using Stokes proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach.
  • Antisense Oligonucleotides Increase Scn1a Expression and Reduce Seizures and SUDEP Incidence in a Mouse Model of Dravet Syndrome, is now available online at: https://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aaz6100 .
  • Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome.

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

Retrieved on: 
Monday, November 25, 2019

Data will be presented from preclinical studies demonstrating the effects of STK-001, a proprietary antisense oligonucleotide (ASO), in the Scn1a-linked Dravet syndrome mouse model and in non-human primates.

Key Points: 
  • Data will be presented from preclinical studies demonstrating the effects of STK-001, a proprietary antisense oligonucleotide (ASO), in the Scn1a-linked Dravet syndrome mouse model and in non-human primates.
  • Approximately 85% of Dravet syndrome cases are caused by spontaneous, heterozygous loss of function mutations in the SCN1A gene, resulting in 50% Nav1.1 protein expression.
  • Stoke has generated preclinical data demonstrating proof-of-mechanism for STK-001.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.

Epilepsy Foundation and The Cameron Boyce Foundation Launch Initiative to Raise Awareness about Epilepsy and the Risk of SUDEP

Retrieved on: 
Wednesday, November 13, 2019

LANDOVER, Md.and LOS ANGELES, Nov. 13, 2019 /PRNewswire/ --Epilepsy Foundation and The Cameron Boyce Foundation launched a new initiative called " K(NO)W SUDEP NOW " to raise awareness about epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), particularly among youth and young adults.

Key Points: 
  • LANDOVER, Md.and LOS ANGELES, Nov. 13, 2019 /PRNewswire/ --Epilepsy Foundation and The Cameron Boyce Foundation launched a new initiative called " K(NO)W SUDEP NOW " to raise awareness about epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), particularly among youth and young adults.
  • "K(NO)W SUDEP NOW is about accelerating research and education to end SUDEP," said Sally Schaeffer, senior director of the Epilepsy Foundation's SUDEP Institute.
  • Improving public awareness of epilepsy and SUDEP will drive more research dollars to help end SUDEP and END EPILEPSY.
  • Following the passing of their son Cameron Boyce due to SUDEP, Victor and Libby expanded the focus of the foundation Cameron had established earlier this year to include epilepsy and SUDEP.

Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome

Retrieved on: 
Friday, October 25, 2019

These data continue to demonstrate the significant clinical impact Fintepla has shown in studies of Dravet syndrome patients, said Bradley Galer, M.D., Executive Vice President and Chief Medical Officer at Zogenix.

Key Points: 
  • These data continue to demonstrate the significant clinical impact Fintepla has shown in studies of Dravet syndrome patients, said Bradley Galer, M.D., Executive Vice President and Chief Medical Officer at Zogenix.
  • Dravet syndrome patients commonly experience generalized tonic-clonic seizures, which are often treatment resistant and have been identified as a major risk factor for SUDEP.
  • We believe that the apparent dose-response effect observed could suggest an important contribution of seizure control or drug effect on executive function in Dravet syndrome patients.
  • The Company anticipates top-line data for FINTEPLA in Lennox-Gastaut syndrome in the first quarter of 2020.

Epilepsy Foundation Awards $300,000 in Grants to Support the Commercialization of Two Novel Approaches for the Treatment of Epilepsy

Retrieved on: 
Tuesday, January 22, 2019

The grants were based on potential for impact and value to patients, likelihood of successful development including regulatory approval and the development timeframe.

Key Points: 
  • The grants were based on potential for impact and value to patients, likelihood of successful development including regulatory approval and the development timeframe.
  • The grants are part of the Foundation's Epilepsy Therapy Project, a research program that seeks to advance innovative ideas in epilepsy, seizure treatment, and care in a timeframe that matters.
  • In 2007, the Epilepsy Foundation awarded a grant to UCLA School of Medicine to support a clinical trial for trigeminal nerve stimulation in those with poorly controlled epilepsy.
  • To apply for the next cycle of the New Therapy Commercialization Grant and Epilepsy Seal of Innovation Award, please visit epilepsy.com/researchgrants .